Cytokines Elevated in HIV Elite Controllers Reduce HIV Replication In Vitro and Modulate HIV Restriction Factor Expression

A subset of HIV-infected individuals termed elite controllers (ECs) maintain CD4 + T cell counts and control viral replication in the absence of antiretroviral therapy (ART). Systemic cytokine responses may differentiate ECs from subjects with uncontrolled viral replication or from those who require...

Full description

Saved in:
Bibliographic Details
Published inJournal of virology Vol. 91; no. 6
Main Authors Jacobs, Evan S., Keating, Sheila M., Abdel-Mohsen, Mohamed, Gibb, Stuart L., Heitman, John W., Inglis, Heather C., Martin, Jeffrey N., Zhang, Jinbing, Kaidarova, Zhanna, Deng, Xutao, Wu, Shiquan, Anastos, Kathryn, Crystal, Howard, Villacres, Maria C., Young, Mary, Greenblatt, Ruth M., Landay, Alan L., Gange, Stephen J., Deeks, Steven G., Golub, Elizabeth T., Pillai, Satish K., Norris, Philip J.
Format Journal Article
LanguageEnglish
Published United States American Society for Microbiology 15.03.2017
Subjects
Online AccessGet full text

Cover

Loading…
Abstract A subset of HIV-infected individuals termed elite controllers (ECs) maintain CD4 + T cell counts and control viral replication in the absence of antiretroviral therapy (ART). Systemic cytokine responses may differentiate ECs from subjects with uncontrolled viral replication or from those who require ART to suppress viral replication. We measured 87 cytokines in four groups of women: 73 ECs, 42 with pharmacologically suppressed viremia (ART), 42 with uncontrolled viral replication (noncontrollers [NCs]), and 48 HIV-uninfected (NEG) subjects. Four cytokines were elevated in ECs but not NCs or ART subjects: CCL14, CCL21, CCL27, and XCL1. In addition, median stromal cell-derived factor-1 (SDF-1) levels were 43% higher in ECs than in NCs. The combination of the five cytokines suppressed R5 and X4 virus replication in resting CD4 + T cells, and individually SDF-1β, CCL14, and CCL27 suppressed R5 virus replication, while SDF-1β, CCL21, and CCL14 suppressed X4 virus replication. Functional studies revealed that the combination of the five cytokines upregulated CD69 and CCR5 and downregulated CXCR4 and CCR7 on CD4 + T cells. The CD69 and CXCR4 effects were driven by SDF-1, while CCL21 downregulated CCR7. The combination of the EC-associated cytokines induced expression of the anti-HIV host restriction factors IFITM1 and IFITM2 and suppressed expression of RNase L and SAMHD1. These results identify a set of cytokines that are elevated in ECs and define their effects on cellular activation, HIV coreceptor expression, and innate restriction factor expression. This cytokine pattern may be a signature characteristic of HIV-1 elite control, potentially important for HIV therapeutic and curative strategies. IMPORTANCE Approximately 1% of people infected with HIV control virus replication without taking antiviral medications. These subjects, termed elite controllers (ECs), are known to have stronger immune responses targeting HIV than the typical HIV-infected subject, but the exact mechanisms of how their immune responses control infection are not known. In this study, we identified five soluble immune signaling molecules (cytokines) in the blood that were higher in ECs than in subjects with typical chronic HIV infection. We demonstrated that these cytokines can activate CD4 + T cells, the target cells for HIV infection. Furthermore, these five EC-associated cytokines could change expression levels of intrinsic resistance factors, or molecules inside the target cell that fight HIV infection. This study is significant in that it identified cytokines elevated in subjects with a good immune response against HIV and defined potential mechanisms as to how these cytokines could induce resistance to the virus in target cells.
AbstractList A subset of HIV-infected individuals termed elite controllers (ECs) maintain CD4+ T cell counts and control viral replication in the absence of antiretroviral therapy (ART). Systemic cytokine responses may differentiate ECs from subjects with uncontrolled viral replication or from those who require ART to suppress viral replication. We measured 87 cytokines in four groups of women: 73 ECs, 42 with pharmacologically suppressed viremia (ART), 42 with uncontrolled viral replication (noncontrollers [NCs]), and 48 HIV-uninfected (NEG) subjects. Four cytokines were elevated in ECs but not NCs or ART subjects: CCL14, CCL21, CCL27, and XCL1. In addition, median stromal cell-derived factor-1 (SDF-1) levels were 43% higher in ECs than in NCs. The combination of the five cytokines suppressed R5 and X4 virus replication in resting CD4+ T cells, and individually SDF-1β, CCL14, and CCL27 suppressed R5 virus replication, while SDF-1β, CCL21, and CCL14 suppressed X4 virus replication. Functional studies revealed that the combination of the five cytokines upregulated CD69 and CCR5 and downregulated CXCR4 and CCR7 on CD4+ T cells. The CD69 and CXCR4 effects were driven by SDF-1, while CCL21 downregulated CCR7. The combination of the EC-associated cytokines induced expression of the anti-HIV host restriction factors IFITM1 and IFITM2 and suppressed expression of RNase L and SAMHD1. These results identify a set of cytokines that are elevated in ECs and define their effects on cellular activation, HIV coreceptor expression, and innate restriction factor expression. This cytokine pattern may be a signature characteristic of HIV-1 elite control, potentially important for HIV therapeutic and curative strategies.IMPORTANCE Approximately 1% of people infected with HIV control virus replication without taking antiviral medications. These subjects, termed elite controllers (ECs), are known to have stronger immune responses targeting HIV than the typical HIV-infected subject, but the exact mechanisms of how their immune responses control infection are not known. In this study, we identified five soluble immune signaling molecules (cytokines) in the blood that were higher in ECs than in subjects with typical chronic HIV infection. We demonstrated that these cytokines can activate CD4+ T cells, the target cells for HIV infection. Furthermore, these five EC-associated cytokines could change expression levels of intrinsic resistance factors, or molecules inside the target cell that fight HIV infection. This study is significant in that it identified cytokines elevated in subjects with a good immune response against HIV and defined potential mechanisms as to how these cytokines could induce resistance to the virus in target cells.A subset of HIV-infected individuals termed elite controllers (ECs) maintain CD4+ T cell counts and control viral replication in the absence of antiretroviral therapy (ART). Systemic cytokine responses may differentiate ECs from subjects with uncontrolled viral replication or from those who require ART to suppress viral replication. We measured 87 cytokines in four groups of women: 73 ECs, 42 with pharmacologically suppressed viremia (ART), 42 with uncontrolled viral replication (noncontrollers [NCs]), and 48 HIV-uninfected (NEG) subjects. Four cytokines were elevated in ECs but not NCs or ART subjects: CCL14, CCL21, CCL27, and XCL1. In addition, median stromal cell-derived factor-1 (SDF-1) levels were 43% higher in ECs than in NCs. The combination of the five cytokines suppressed R5 and X4 virus replication in resting CD4+ T cells, and individually SDF-1β, CCL14, and CCL27 suppressed R5 virus replication, while SDF-1β, CCL21, and CCL14 suppressed X4 virus replication. Functional studies revealed that the combination of the five cytokines upregulated CD69 and CCR5 and downregulated CXCR4 and CCR7 on CD4+ T cells. The CD69 and CXCR4 effects were driven by SDF-1, while CCL21 downregulated CCR7. The combination of the EC-associated cytokines induced expression of the anti-HIV host restriction factors IFITM1 and IFITM2 and suppressed expression of RNase L and SAMHD1. These results identify a set of cytokines that are elevated in ECs and define their effects on cellular activation, HIV coreceptor expression, and innate restriction factor expression. This cytokine pattern may be a signature characteristic of HIV-1 elite control, potentially important for HIV therapeutic and curative strategies.IMPORTANCE Approximately 1% of people infected with HIV control virus replication without taking antiviral medications. These subjects, termed elite controllers (ECs), are known to have stronger immune responses targeting HIV than the typical HIV-infected subject, but the exact mechanisms of how their immune responses control infection are not known. In this study, we identified five soluble immune signaling molecules (cytokines) in the blood that were higher in ECs than in subjects with typical chronic HIV infection. We demonstrated that these cytokines can activate CD4+ T cells, the target cells for HIV infection. Furthermore, these five EC-associated cytokines could change expression levels of intrinsic resistance factors, or molecules inside the target cell that fight HIV infection. This study is significant in that it identified cytokines elevated in subjects with a good immune response against HIV and defined potential mechanisms as to how these cytokines could induce resistance to the virus in target cells.
A subset of HIV-infected individuals termed elite controllers (ECs) maintain CD4 + T cell counts and control viral replication in the absence of antiretroviral therapy (ART). Systemic cytokine responses may differentiate ECs from subjects with uncontrolled viral replication or from those who require ART to suppress viral replication. We measured 87 cytokines in four groups of women: 73 ECs, 42 with pharmacologically suppressed viremia (ART), 42 with uncontrolled viral replication (noncontrollers [NCs]), and 48 HIV-uninfected (NEG) subjects. Four cytokines were elevated in ECs but not NCs or ART subjects: CCL14, CCL21, CCL27, and XCL1. In addition, median stromal cell-derived factor-1 (SDF-1) levels were 43% higher in ECs than in NCs. The combination of the five cytokines suppressed R5 and X4 virus replication in resting CD4 + T cells, and individually SDF-1β, CCL14, and CCL27 suppressed R5 virus replication, while SDF-1β, CCL21, and CCL14 suppressed X4 virus replication. Functional studies revealed that the combination of the five cytokines upregulated CD69 and CCR5 and downregulated CXCR4 and CCR7 on CD4 + T cells. The CD69 and CXCR4 effects were driven by SDF-1, while CCL21 downregulated CCR7. The combination of the EC-associated cytokines induced expression of the anti-HIV host restriction factors IFITM1 and IFITM2 and suppressed expression of RNase L and SAMHD1. These results identify a set of cytokines that are elevated in ECs and define their effects on cellular activation, HIV coreceptor expression, and innate restriction factor expression. This cytokine pattern may be a signature characteristic of HIV-1 elite control, potentially important for HIV therapeutic and curative strategies. IMPORTANCE Approximately 1% of people infected with HIV control virus replication without taking antiviral medications. These subjects, termed elite controllers (ECs), are known to have stronger immune responses targeting HIV than the typical HIV-infected subject, but the exact mechanisms of how their immune responses control infection are not known. In this study, we identified five soluble immune signaling molecules (cytokines) in the blood that were higher in ECs than in subjects with typical chronic HIV infection. We demonstrated that these cytokines can activate CD4 + T cells, the target cells for HIV infection. Furthermore, these five EC-associated cytokines could change expression levels of intrinsic resistance factors, or molecules inside the target cell that fight HIV infection. This study is significant in that it identified cytokines elevated in subjects with a good immune response against HIV and defined potential mechanisms as to how these cytokines could induce resistance to the virus in target cells.
A subset of HIV-infected individuals termed elite controllers (ECs) maintain CD4 T cell counts and control viral replication in the absence of antiretroviral therapy (ART). Systemic cytokine responses may differentiate ECs from subjects with uncontrolled viral replication or from those who require ART to suppress viral replication. We measured 87 cytokines in four groups of women: 73 ECs, 42 with pharmacologically suppressed viremia (ART), 42 with uncontrolled viral replication (noncontrollers [NCs]), and 48 HIV-uninfected (NEG) subjects. Four cytokines were elevated in ECs but not NCs or ART subjects: CCL14, CCL21, CCL27, and XCL1. In addition, median stromal cell-derived factor-1 (SDF-1) levels were 43% higher in ECs than in NCs. The combination of the five cytokines suppressed R5 and X4 virus replication in resting CD4 T cells, and individually SDF-1β, CCL14, and CCL27 suppressed R5 virus replication, while SDF-1β, CCL21, and CCL14 suppressed X4 virus replication. Functional studies revealed that the combination of the five cytokines upregulated CD69 and CCR5 and downregulated CXCR4 and CCR7 on CD4 T cells. The CD69 and CXCR4 effects were driven by SDF-1, while CCL21 downregulated CCR7. The combination of the EC-associated cytokines induced expression of the anti-HIV host restriction factors IFITM1 and IFITM2 and suppressed expression of RNase L and SAMHD1. These results identify a set of cytokines that are elevated in ECs and define their effects on cellular activation, HIV coreceptor expression, and innate restriction factor expression. This cytokine pattern may be a signature characteristic of HIV-1 elite control, potentially important for HIV therapeutic and curative strategies. Approximately 1% of people infected with HIV control virus replication without taking antiviral medications. These subjects, termed elite controllers (ECs), are known to have stronger immune responses targeting HIV than the typical HIV-infected subject, but the exact mechanisms of how their immune responses control infection are not known. In this study, we identified five soluble immune signaling molecules (cytokines) in the blood that were higher in ECs than in subjects with typical chronic HIV infection. We demonstrated that these cytokines can activate CD4 T cells, the target cells for HIV infection. Furthermore, these five EC-associated cytokines could change expression levels of intrinsic resistance factors, or molecules inside the target cell that fight HIV infection. This study is significant in that it identified cytokines elevated in subjects with a good immune response against HIV and defined potential mechanisms as to how these cytokines could induce resistance to the virus in target cells.
Author Deng, Xutao
Anastos, Kathryn
Deeks, Steven G.
Crystal, Howard
Pillai, Satish K.
Young, Mary
Kaidarova, Zhanna
Abdel-Mohsen, Mohamed
Villacres, Maria C.
Norris, Philip J.
Gibb, Stuart L.
Golub, Elizabeth T.
Keating, Sheila M.
Heitman, John W.
Greenblatt, Ruth M.
Gange, Stephen J.
Jacobs, Evan S.
Martin, Jeffrey N.
Inglis, Heather C.
Zhang, Jinbing
Landay, Alan L.
Wu, Shiquan
Author_xml – sequence: 1
  givenname: Evan S.
  surname: Jacobs
  fullname: Jacobs, Evan S.
  organization: Blood Systems Research Institute, San Francisco, California, USA
– sequence: 2
  givenname: Sheila M.
  surname: Keating
  fullname: Keating, Sheila M.
  organization: Blood Systems Research Institute, San Francisco, California, USA, Department of Laboratory Medicine, University of California, San Francisco, San Francisco, California, USA
– sequence: 3
  givenname: Mohamed
  surname: Abdel-Mohsen
  fullname: Abdel-Mohsen, Mohamed
  organization: Blood Systems Research Institute, San Francisco, California, USA, Department of Medicine, University of California, San Francisco, San Francisco, California, USA
– sequence: 4
  givenname: Stuart L.
  surname: Gibb
  fullname: Gibb, Stuart L.
  organization: Blood Systems Research Institute, San Francisco, California, USA
– sequence: 5
  givenname: John W.
  surname: Heitman
  fullname: Heitman, John W.
  organization: Blood Systems Research Institute, San Francisco, California, USA
– sequence: 6
  givenname: Heather C.
  surname: Inglis
  fullname: Inglis, Heather C.
  organization: Blood Systems Research Institute, San Francisco, California, USA
– sequence: 7
  givenname: Jeffrey N.
  surname: Martin
  fullname: Martin, Jeffrey N.
  organization: Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA
– sequence: 8
  givenname: Jinbing
  surname: Zhang
  fullname: Zhang, Jinbing
  organization: Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
– sequence: 9
  givenname: Zhanna
  surname: Kaidarova
  fullname: Kaidarova, Zhanna
  organization: Blood Systems Research Institute, San Francisco, California, USA
– sequence: 10
  givenname: Xutao
  surname: Deng
  fullname: Deng, Xutao
  organization: Blood Systems Research Institute, San Francisco, California, USA
– sequence: 11
  givenname: Shiquan
  surname: Wu
  fullname: Wu, Shiquan
  organization: Blood Systems Research Institute, San Francisco, California, USA
– sequence: 12
  givenname: Kathryn
  surname: Anastos
  fullname: Anastos, Kathryn
  organization: Albert Einstein College of Medicine, Bronx, New York, USA
– sequence: 13
  givenname: Howard
  surname: Crystal
  fullname: Crystal, Howard
  organization: SUNY Downstate Medical Center, Brooklyn, New York, USA
– sequence: 14
  givenname: Maria C.
  surname: Villacres
  fullname: Villacres, Maria C.
  organization: Keck School of Medicine of the University of Southern California, Los Angeles, California, USA
– sequence: 15
  givenname: Mary
  surname: Young
  fullname: Young, Mary
  organization: Georgetown University Medical Center, Washington, DC, USA
– sequence: 16
  givenname: Ruth M.
  surname: Greenblatt
  fullname: Greenblatt, Ruth M.
  organization: Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA, Department of Pharmacy, University of California, San Francisco, San Francisco, California, USA, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
– sequence: 17
  givenname: Alan L.
  surname: Landay
  fullname: Landay, Alan L.
  organization: Rush University Medical Center, Chicago, Illinois, USA
– sequence: 18
  givenname: Stephen J.
  surname: Gange
  fullname: Gange, Stephen J.
  organization: Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
– sequence: 19
  givenname: Steven G.
  surname: Deeks
  fullname: Deeks, Steven G.
  organization: Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA
– sequence: 20
  givenname: Elizabeth T.
  surname: Golub
  fullname: Golub, Elizabeth T.
  organization: Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
– sequence: 21
  givenname: Satish K.
  surname: Pillai
  fullname: Pillai, Satish K.
  organization: Blood Systems Research Institute, San Francisco, California, USA, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA
– sequence: 22
  givenname: Philip J.
  orcidid: 0000-0003-0526-2088
  surname: Norris
  fullname: Norris, Philip J.
  organization: Blood Systems Research Institute, San Francisco, California, USA, Department of Laboratory Medicine, University of California, San Francisco, San Francisco, California, USA, Department of Medicine, University of California, San Francisco, San Francisco, California, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28053103$$D View this record in MEDLINE/PubMed
BookMark eNptkc1vVCEUxYmpsdPRnWvD0oWvwgPex8bETKZ2mjYmjU7cER7cpygDU-A11r--dDpttHFF4P445957jtCBDx4Qek3JMaV19_5svTomNRG0os0zNKOk7yohKD9AM0LquhKs-3aIjlL6SQjlvOEv0GHdEcEoYTP0Z3GTwy_rIeGlg2uVwWDr8elqXe42A14En2NwDmLCl2AmDbviJWyd1Srb4PHK47UtEFbe4ItgJldk9lTK0eoddaJ0DhEvf28jpFReXqLno3IJXu3POfp6svyyOK3OP39aLT6eV5rxJlejaUvTnPSc1Ya1CgbFlAEG0ALXSvSGMsLU0LQDJd1oGmGaoVeDHtoiMI5sjj7c626nYQNGQxlIObmNdqPijQzKyn8r3v6Q38O1FIzRttjO0du9QAxXUxlJbmzS4JzyEKYkaSdE2zW8pwV987fXo8nDwgvw7h7QMaQUYXxEKJF3ecqSp9zlKWlT8PoJrm3ebb10at3_P90CABylPg
CitedBy_id crossref_primary_10_1155_2018_8357109
crossref_primary_10_1371_journal_pone_0306559
crossref_primary_10_3390_ijms24054958
crossref_primary_10_1016_j_ebiom_2017_11_031
crossref_primary_10_1002_JLB_3MR0717_307R
crossref_primary_10_3389_fimmu_2021_649465
crossref_primary_10_1016_S2352_3018_18_30039_0
crossref_primary_10_1097_QAI_0000000000003518
crossref_primary_10_1007_s11262_019_01721_8
crossref_primary_10_1186_s13059_025_03484_y
crossref_primary_10_12688_f1000research_15029_1
crossref_primary_10_1016_j_micinf_2020_05_019
crossref_primary_10_3390_biom15030432
crossref_primary_10_3389_fimmu_2021_687296
crossref_primary_10_1186_s13058_020_01373_9
crossref_primary_10_1002_iid3_70138
crossref_primary_10_1016_j_domaniend_2019_106404
crossref_primary_10_1016_S2055_6640_20_30046_7
crossref_primary_10_1371_journal_ppat_1006806
crossref_primary_10_1101_gr_241372_118
crossref_primary_10_3389_fmicb_2022_912908
crossref_primary_10_3389_fimmu_2021_634832
crossref_primary_10_1097_QAD_0000000000002279
crossref_primary_10_1177_026119291704500406
crossref_primary_10_1016_j_cyto_2019_154839
crossref_primary_10_3390_molecules25204829
Cites_doi 10.1021/acschembio.5b00542
10.1097/QAD.0b013e3283489d1f
10.1128/AAC.46.4.982-990.2002
10.1126/science.278.5342.1447
10.1038/382833a0
10.1006/viro.1999.0011
10.1128/JVI.01763-08
10.1097/QAD.0b013e32831cf595
10.1128/jvi.69.7.4228-4236.1995
10.1128/JVI.00056-12
10.1038/gt.2009.112
10.1172/JCI44539
10.1038/417095a
10.1128/jvi.69.9.5743-5753.1995
10.1182/blood-2010-12-327106
10.1016/j.chom.2014.11.001
10.1128/JVI.02165-06
10.1084/jem.192.10.1501
10.1016/j.virol.2014.01.020
10.1128/JVI.00728-14
10.7326/0003-4819-113-6-438
10.1126/science.1195271
10.1128/JVI.05327-11
10.1016/j.cell.2016.06.039
10.1086/315128
10.1126/science.1143767
10.1007/s11904-016-0296-x
10.1073/pnas.1111573109
10.1089/aid.2010.0161
10.1182/blood-2010-09-309591
10.1042/CS20160112
10.1016/j.cytogfr.2012.05.006
10.1089/aid.2015.0226
10.1016/j.celrep.2015.08.055
10.1093/emboj/16.23.6996
10.1182/blood-2007-06-097907
10.1128/JVI.01531-10
10.1371/journal.ppat.1003852
10.1128/JVI.01285-15
10.1086/314660
10.1097/00002030-199607000-00005
10.1006/geno.1995.1180
10.1097/QAI.0000000000001166
10.1371/journal.pmed.0050203
10.1097/QAD.0b013e32835a9950
10.1016/j.vaccine.2009.10.095
10.1016/j.micinf.2012.12.003
10.1371/journal.pone.0118794
10.1111/j.1365-2249.2009.03976.x
10.1182/blood.V92.9.3105.421k46_3105_3114
10.1097/01.qai.0000219786.88786.d8
10.1517/14712598.3.1.15
10.1128/JVI.79.22.14169-14178.2005
10.1186/gb-2002-3-7-research0034
10.1073/pnas.1108866108
10.1128/jvi.68.9.6103-6110.1994
10.1111/j.1468-3083.2012.04592.x
10.1111/j.2517-6161.1995.tb02031.x
10.1038/382829a0
10.4049/jimmunol.0903915
10.1097/00002030-199816000-00006
10.1128/JVI.00800-08
10.1084/jem.164.6.1988
10.1128/JVI.00118-15
10.1128/jvi.68.7.4650-4655.1994
10.1097/QAD.0b013e3283377a1e
10.3390/ijms17030413
10.1097/QAD.0b013e3283367836
ContentType Journal Article
Copyright Copyright © 2017 American Society for Microbiology.
Copyright © 2017 American Society for Microbiology. 2017 American Society for Microbiology
Copyright_xml – notice: Copyright © 2017 American Society for Microbiology.
– notice: Copyright © 2017 American Society for Microbiology. 2017 American Society for Microbiology
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1128/JVI.02051-16
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
DocumentTitleAlternate Cytokines Elevated in HIV Elite Controllers
EISSN 1098-5514
ExternalDocumentID PMC5331794
28053103
10_1128_JVI_02051_16
Genre Journal Article
GrantInformation_xml – fundername: NIGMS NIH HHS
  grantid: R01 GM117901
– fundername: NIAID NIH HHS
  grantid: P30 AI027763
– fundername: NIAID NIH HHS
  grantid: R01 AI150449
– fundername: HHS | National Institutes of Health (NIH)
  grantid: U01-AI-034989
– fundername: HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
  grantid: P30 AI027763
– fundername: HHS | National Institutes of Health (NIH)
  grantid: UL1-TR000454
– fundername: HHS | National Institutes of Health (NIH)
  grantid: U01-AI-031834
– fundername: HHS | National Institutes of Health (NIH)
  grantid: U01-AI-034993
– fundername: HHS | National Institutes of Health (NIH)
  grantid: UL1-TR000004
– fundername: HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
  grantid: R24 AI067039
– fundername: HHS | National Institutes of Health (NIH)
  grantid: U01-AI-042590
– fundername: HHS | National Institutes of Health (NIH)
  grantid: U01-AI-035004
– fundername: HHS | National Institutes of Health (NIH)
  grantid: U01-AI-034994
GroupedDBID ---
-~X
0R~
18M
29L
2WC
39C
4.4
53G
5GY
5RE
5VS
85S
AAFWJ
AAGFI
AAYXX
ABPPZ
ACGFO
ACNCT
ADBBV
AENEX
AGVNZ
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BTFSW
CITATION
CS3
DIK
E3Z
EBS
EJD
F5P
FRP
GX1
H13
HYE
HZ~
IH2
KQ8
N9A
O9-
OK1
P2P
RHI
RNS
RPM
RSF
TR2
UPT
W2D
W8F
WH7
WOQ
YQT
~02
~KM
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-c346t-fd7464409432d37aeba3ade3ee7e4ca59d1303ab67b108fd65d6b9abcb7c34ff3
ISSN 0022-538X
1098-5514
IngestDate Thu Aug 21 18:24:53 EDT 2025
Thu Jul 10 17:33:13 EDT 2025
Thu Apr 03 07:06:40 EDT 2025
Tue Jul 01 01:02:48 EDT 2025
Thu Apr 24 22:56:15 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords restriction factor
chemokine receptors
cytokines
HIV
elite control
Language English
License Copyright © 2017 American Society for Microbiology.
All Rights Reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c346t-fd7464409432d37aeba3ade3ee7e4ca59d1303ab67b108fd65d6b9abcb7c34ff3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Citation Jacobs ES, Keating SM, Abdel-Mohsen M, Gibb SL, Heitman JW, Inglis HC, Martin JN, Zhang J, Kaidarova Z, Deng X, Wu S, Anastos K, Crystal H, Villacres MC, Young M, Greenblatt RM, Landay AL, Gange SJ, Deeks SG, Golub ET, Pillai SK, Norris PJ, the Women's Interagency HIV Study. 2017. Cytokines elevated in HIV elite controllers reduce HIV replication in vitro and modulate HIV restriction factor expression. J Virol 91:e02051-16. https://doi.org/10.1128/JVI.02051-16.
E.S.J. and S.M.K. contributed equally to this article.
ORCID 0000-0003-0526-2088
PMID 28053103
PQID 1855786491
PQPubID 23479
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5331794
proquest_miscellaneous_1855786491
pubmed_primary_28053103
crossref_primary_10_1128_JVI_02051_16
crossref_citationtrail_10_1128_JVI_02051_16
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2017-03-15
PublicationDateYYYYMMDD 2017-03-15
PublicationDate_xml – month: 03
  year: 2017
  text: 2017-03-15
  day: 15
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: 1752 N St., N.W., Washington, DC
PublicationTitle Journal of virology
PublicationTitleAlternate J Virol
PublicationYear 2017
Publisher American Society for Microbiology
Publisher_xml – name: American Society for Microbiology
References e_1_3_2_26_2
e_1_3_2_49_2
e_1_3_2_28_2
e_1_3_2_41_2
e_1_3_2_64_2
e_1_3_2_20_2
e_1_3_2_43_2
e_1_3_2_62_2
e_1_3_2_22_2
e_1_3_2_45_2
e_1_3_2_68_2
e_1_3_2_24_2
e_1_3_2_47_2
e_1_3_2_66_2
e_1_3_2_60_2
e_1_3_2_9_2
e_1_3_2_16_2
e_1_3_2_37_2
e_1_3_2_7_2
e_1_3_2_18_2
e_1_3_2_39_2
e_1_3_2_54_2
e_1_3_2_10_2
e_1_3_2_31_2
e_1_3_2_52_2
e_1_3_2_5_2
e_1_3_2_12_2
e_1_3_2_33_2
e_1_3_2_58_2
e_1_3_2_3_2
e_1_3_2_14_2
e_1_3_2_35_2
e_1_3_2_56_2
e_1_3_2_50_2
e_1_3_2_27_2
e_1_3_2_48_2
e_1_3_2_29_2
e_1_3_2_40_2
e_1_3_2_65_2
e_1_3_2_21_2
e_1_3_2_42_2
e_1_3_2_63_2
e_1_3_2_23_2
e_1_3_2_44_2
e_1_3_2_25_2
e_1_3_2_46_2
e_1_3_2_67_2
e_1_3_2_61_2
Benjamini Y (e_1_3_2_69_2) 1995; 57
e_1_3_2_15_2
e_1_3_2_38_2
e_1_3_2_8_2
e_1_3_2_17_2
e_1_3_2_59_2
e_1_3_2_6_2
e_1_3_2_19_2
e_1_3_2_30_2
e_1_3_2_53_2
e_1_3_2_32_2
e_1_3_2_51_2
e_1_3_2_11_2
e_1_3_2_34_2
e_1_3_2_57_2
e_1_3_2_4_2
e_1_3_2_13_2
e_1_3_2_36_2
e_1_3_2_55_2
e_1_3_2_2_2
References_xml – ident: e_1_3_2_55_2
  doi: 10.1021/acschembio.5b00542
– ident: e_1_3_2_11_2
  doi: 10.1097/QAD.0b013e3283489d1f
– ident: e_1_3_2_56_2
  doi: 10.1128/AAC.46.4.982-990.2002
– ident: e_1_3_2_22_2
  doi: 10.1126/science.278.5342.1447
– ident: e_1_3_2_35_2
  doi: 10.1038/382833a0
– ident: e_1_3_2_52_2
  doi: 10.1006/viro.1999.0011
– ident: e_1_3_2_15_2
  doi: 10.1128/JVI.01763-08
– ident: e_1_3_2_49_2
  doi: 10.1097/QAD.0b013e32831cf595
– ident: e_1_3_2_18_2
  doi: 10.1128/jvi.69.7.4228-4236.1995
– ident: e_1_3_2_23_2
  doi: 10.1128/JVI.00056-12
– ident: e_1_3_2_48_2
  doi: 10.1038/gt.2009.112
– ident: e_1_3_2_24_2
  doi: 10.1172/JCI44539
– ident: e_1_3_2_59_2
  doi: 10.1038/417095a
– ident: e_1_3_2_17_2
  doi: 10.1128/jvi.69.9.5743-5753.1995
– ident: e_1_3_2_25_2
  doi: 10.1182/blood-2010-12-327106
– ident: e_1_3_2_62_2
  doi: 10.1016/j.chom.2014.11.001
– ident: e_1_3_2_19_2
  doi: 10.1128/JVI.02165-06
– ident: e_1_3_2_33_2
  doi: 10.1084/jem.192.10.1501
– ident: e_1_3_2_66_2
  doi: 10.1016/j.virol.2014.01.020
– ident: e_1_3_2_3_2
  doi: 10.1128/JVI.00728-14
– ident: e_1_3_2_4_2
  doi: 10.7326/0003-4819-113-6-438
– ident: e_1_3_2_28_2
  doi: 10.1126/science.1195271
– ident: e_1_3_2_27_2
  doi: 10.1128/JVI.05327-11
– ident: e_1_3_2_60_2
  doi: 10.1016/j.cell.2016.06.039
– ident: e_1_3_2_21_2
  doi: 10.1086/315128
– ident: e_1_3_2_30_2
  doi: 10.1126/science.1143767
– ident: e_1_3_2_13_2
  doi: 10.1007/s11904-016-0296-x
– ident: e_1_3_2_39_2
  doi: 10.1073/pnas.1111573109
– ident: e_1_3_2_42_2
  doi: 10.1089/aid.2010.0161
– ident: e_1_3_2_12_2
  doi: 10.1182/blood-2010-09-309591
– ident: e_1_3_2_31_2
  doi: 10.1042/CS20160112
– ident: e_1_3_2_40_2
  doi: 10.1016/j.cytogfr.2012.05.006
– ident: e_1_3_2_43_2
  doi: 10.1089/aid.2015.0226
– ident: e_1_3_2_63_2
  doi: 10.1016/j.celrep.2015.08.055
– ident: e_1_3_2_58_2
  doi: 10.1093/emboj/16.23.6996
– ident: e_1_3_2_51_2
  doi: 10.1182/blood-2007-06-097907
– ident: e_1_3_2_61_2
  doi: 10.1128/JVI.01531-10
– ident: e_1_3_2_36_2
  doi: 10.1371/journal.ppat.1003852
– ident: e_1_3_2_54_2
  doi: 10.1128/JVI.01285-15
– ident: e_1_3_2_7_2
  doi: 10.1086/314660
– ident: e_1_3_2_8_2
  doi: 10.1097/00002030-199607000-00005
– ident: e_1_3_2_57_2
  doi: 10.1006/geno.1995.1180
– ident: e_1_3_2_67_2
  doi: 10.1097/QAI.0000000000001166
– ident: e_1_3_2_9_2
  doi: 10.1371/journal.pmed.0050203
– ident: e_1_3_2_32_2
  doi: 10.1097/QAD.0b013e32835a9950
– ident: e_1_3_2_47_2
  doi: 10.1016/j.vaccine.2009.10.095
– ident: e_1_3_2_64_2
  doi: 10.1016/j.micinf.2012.12.003
– ident: e_1_3_2_65_2
  doi: 10.1371/journal.pone.0118794
– ident: e_1_3_2_50_2
  doi: 10.1111/j.1365-2249.2009.03976.x
– ident: e_1_3_2_14_2
  doi: 10.1182/blood.V92.9.3105.421k46_3105_3114
– ident: e_1_3_2_29_2
  doi: 10.1097/01.qai.0000219786.88786.d8
– ident: e_1_3_2_46_2
  doi: 10.1517/14712598.3.1.15
– ident: e_1_3_2_37_2
  doi: 10.1128/JVI.79.22.14169-14178.2005
– ident: e_1_3_2_68_2
  doi: 10.1186/gb-2002-3-7-research0034
– ident: e_1_3_2_26_2
  doi: 10.1073/pnas.1108866108
– ident: e_1_3_2_5_2
  doi: 10.1128/jvi.68.9.6103-6110.1994
– ident: e_1_3_2_45_2
  doi: 10.1111/j.1468-3083.2012.04592.x
– volume: 57
  start-page: 289
  year: 1995
  ident: e_1_3_2_69_2
  article-title: Controlling the false discovery rate: a practical and powerful approach to multiple testing
  publication-title: J R Stat Soc B
  doi: 10.1111/j.2517-6161.1995.tb02031.x
– ident: e_1_3_2_34_2
  doi: 10.1038/382829a0
– ident: e_1_3_2_41_2
  doi: 10.4049/jimmunol.0903915
– ident: e_1_3_2_10_2
  doi: 10.1097/00002030-199816000-00006
– ident: e_1_3_2_20_2
  doi: 10.1128/JVI.00800-08
– ident: e_1_3_2_38_2
  doi: 10.1084/jem.164.6.1988
– ident: e_1_3_2_44_2
  doi: 10.1128/JVI.00118-15
– ident: e_1_3_2_6_2
  doi: 10.1128/jvi.68.7.4650-4655.1994
– ident: e_1_3_2_16_2
  doi: 10.1097/QAD.0b013e3283377a1e
– ident: e_1_3_2_53_2
  doi: 10.3390/ijms17030413
– ident: e_1_3_2_2_2
  doi: 10.1097/QAD.0b013e3283367836
SSID ssj0014464
Score 2.3833795
Snippet A subset of HIV-infected individuals termed elite controllers (ECs) maintain CD4 + T cell counts and control viral replication in the absence of antiretroviral...
A subset of HIV-infected individuals termed elite controllers (ECs) maintain CD4 T cell counts and control viral replication in the absence of antiretroviral...
A subset of HIV-infected individuals termed elite controllers (ECs) maintain CD4+ T cell counts and control viral replication in the absence of antiretroviral...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
SubjectTerms Adult
Antigens, Differentiation - biosynthesis
CD4-Positive T-Lymphocytes - virology
Cytokines - metabolism
Female
Gene Expression Regulation
HIV - immunology
HIV - physiology
HIV Infections - immunology
HIV Long-Term Survivors
Humans
Membrane Proteins - biosynthesis
Middle Aged
Pathogenesis and Immunity
Plasma - chemistry
Receptors, HIV - biosynthesis
Virus Replication - drug effects
Title Cytokines Elevated in HIV Elite Controllers Reduce HIV Replication In Vitro and Modulate HIV Restriction Factor Expression
URI https://www.ncbi.nlm.nih.gov/pubmed/28053103
https://www.proquest.com/docview/1855786491
https://pubmed.ncbi.nlm.nih.gov/PMC5331794
Volume 91
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBdbx2AvY9_LvtBgewruEsu27MdSEtrQdrAmJW9GsmQS6tmjdQftX787Sf5Il0K3F2MkRQm-X0535_vdEfLFjyXnecC9MMu0F0hfeLEYSy-Kc84k9noIkZx8fBIdLILZMlx2aUWGXVLL3exmK6_kf6QKYyBXZMn-g2TbTWEA7kG-cAUJw_VeMt6_rqtzzFsfTgr9W6DxiKWrwKObILUY6XyYh14gSfcH1mjVZhKM7iZUB_pheLaGRTbholLYzatZhS09bCfxqenKg3WRbdpseYdNi6S5fph-BvpWWsID8qROO_UuatdM5XSl14XogrJ7UunCO65WLjQEd-KnY2AJ0_Bc2uw0zEZ1nAkXtYCTEFPgwp6ixTqmaK3Zc2jLmNPOtpeXQ2G0Xen7SGSYnR3ugu0b2r7X-a3a2iff0-ni6CidT5bzh-SRD06F38R23DsncIxNDkLzKxqahB9_6--9acD85ZXcTq7tWSvzZ-SpEwnds5h5Th7o8gV5bBuPXr8kNy1yaIMcui4piJ0a5NAecqhFjpnsIYceltQghwJyaIMct6pFDrXIoR1yXpHFdDLfP_BcFw4vY0FUe7ni8GAwDMB8xbjQUjChNNOa6yATYaLQDBIy4nI8inMVhSqSiZCZ5LBBnrPXZKesSv2WUMZiMRIJ5gmoIM5G8Blwl5QUicwVY8mADJtHm2auRD12SilS46r6cQqCSI0g0nE0IF_b1b9saZY71n1upJSC7sQXYqLU1dVlCrYqHFhRkIwH5I2VWruTH-PxNGIDwjfk2S7AuuybM-V6ZeqzgweFx9y7e3zve_Kk-3d8IDv1xZX-CFZuLT8ZcP4BOm6sMw
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cytokines+Elevated+in+HIV+Elite+Controllers+Reduce+HIV+Replication+In+Vitro+and+Modulate+HIV+Restriction+Factor+Expression&rft.jtitle=Journal+of+virology&rft.au=Jacobs%2C+Evan+S&rft.au=Keating%2C+Sheila+M&rft.au=Abdel-Mohsen%2C+Mohamed&rft.au=Gibb%2C+Stuart+L&rft.date=2017-03-15&rft.issn=1098-5514&rft.eissn=1098-5514&rft.volume=91&rft.issue=6&rft_id=info:doi/10.1128%2FJVI.02051-16&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-538X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-538X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-538X&client=summon